Form 4: Director Howard Welgus Executes Arcutis Stock Transactions

Director Howard G. Welgus exercised stock options and sold shares of Arcutis Biotherapeutics, Inc. under a 10b5-1 plan.

Summary

• Director Howard G. Welgus exercised options to acquire 4,096 shares of common stock at prices ranging from $6.52 to $8.63.
• Following the exercise, the director sold 4,731 shares in total across two dates (June 15 and June 17, 2026).
• The sales were executed at weighted average prices of $24.41 and $25.67 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine portfolio management by a director.

Positives

• The director maintains a significant remaining beneficial ownership of 37,743 shares of common stock.
• Transactions were executed under a pre-arranged 10b5-1 plan, indicating systematic rather than reactive trading.

Negatives

• The director reduced their total beneficial ownership position through these sales.

Risks

• Future share price volatility could impact the value of remaining holdings.
• Reliance on 10b5-1 plans does not eliminate market risk for the reporting person.

Future Outlook

The filing does not provide corporate guidance, but notes the 10b5-1 plan remains active until June 15, 2027.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for corporate directors to diversify holdings and is generally viewed as neutral by the market, provided the sales are consistent with pre-established plans.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate insiders to avoid allegations of trading on material non-public information.
• The volume of shares sold is relatively small compared to the total outstanding shares of Arcutis Biotherapeutics.

Stakeholder Impact

• Minimal impact expected on shareholders as the transactions were pre-planned and disclosed.

Next Steps

• Continued execution of the 10b5-1 plan until June 15, 2027.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Insider Trading, Form 4, Biotech, Stock Options